A firm headquartered in Asia with offices in US and Europe invests specifically in companies that are raising funds to carry out clinical trials which can be performed, totally or in part, in an affiliated network of sites located in Europe and Asia. The firm typically invests alongside lead investors with a track record in biotech or medtech, and usually funds a large fraction of clinical trial costs. The firm can fund up to 10-15 trials per year. The size of investments is flexible, scaled to the clinical trial requirements, and will mostly range from 1 to 6 million USD/EUR. Investments made by the firm will fund work performed by a top-tier FDA-inspected network of sites offering clinical studies and CRO services to major pharma companies.

Although focused primarily on therapeutics, the firm also consider diagnostics, medical devices, and digital health companies. The firm is generally indication-agnostic but has a keen interest in fields such as diabetes, pulmonology, ophthalmology and some cancers. The firm is primarily interested in companies running Phase I / Phase II clinical trials or equivalent.

The firm looks to act as a co-investor and will typically not require a board seat. The firm will more often invest when there is a lead investor on board. The firm has no specific requirements for the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global leader in life sciences, diagnostics and applied chemical markets provides services, equipment, and support solutions to laboratories worldwide. The firm has an early stage partnership program that works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit to Agilent’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.

The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Bioproduction Instrumentation, Cell & Gene Therapy Tools, Cellular Engineering and Analysis, Genomics, Lab Data Analytics & Informatics, Molecular Diagnostics and Sample Preparation. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.

The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm headquartered in Western Europe is tied with a dedicated life sciences consulting firm with multiple offices throughout USA, Europe, and Asia. With the capability to leverage the experienced resources from the consulting firm, the firm is able to invest in and support in early-stage technologies with a derisked strategy. The firm has a pan-European focus and is sourcing globally within industry, start-up communities, and business accelerators, for high potential opportunities.

The firm is interested in proprietary, differentiated therapeutic products addressing high-unmet medical need and platform technologies supporting next-generation patient diagnosis, treatment and disease prevention. The interest areas also include genomics, AI, diagnostics, medical devices, rare diseases, next generation personalized medicine, and more. The firm is interested in early-stage opportunities – pre-clinical assets with a valid proof of concept, devices with a working prototype are all good fits in terms of stage of development.

The firm will look at each opportunity carefully, and is most interested in those with business potential with a 3-5 year runway to strategic partnerships, acquisition by large life science companies or an IPO. The firm will prefer to lead investments and will take a very active role in their portfolio companies, often being involved in the operations of these companies to support their growth and enabling research that generates important, proof-of-concept data.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm based in the US looks to invest in healthcare companies of strategic interest to a major healthcare insurance company that the firm has ties with, while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices, and agnostic towards types of technologies and indication areas the technologies address.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech company based in the USA has an active pipeline of therapeutic assets in immuno-oncology and autoimmune diseases. The firm has been seeking novel therapeutics opportunities that are synergistic with the firm’s existing pipeline for potential licensing, investment, and other partnership opportunities. The firm is most interested in opportunities based in US and Europe.

The firm is seeking therapeutic opportunities for potential licensing, investment, and other win-win partnership opportunities. The firm is open to novel targets and modalities; in terms of indication/disease area, the firm is only considering immuno-oncology and autoimmune diseases at this time. In terms of stage of development, the firm will primarily consider pre-clinical stage assets.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly formed corporate VC of a pharmaceutical company is investing from an evergreen fund. The firm is interested in investing in companies in therapeutics, AI/ML drug discovery tools, digital therapeutics, virtual care platforms and connected devices. For therapeutics companies, the firm prefers to invest in companies that are preclinical, before IND. For other companies, the firm prefers to invest close to revenue, post pilot. The firm invests in companies based in North America, Europe and Israel from pre-seed to Series A, and will invest between .5-4M EUR in their first round, with capital reserved for follow on investments.

Historically, the firm has focused on CNS disorders and rare diseases, including areas such as neurodevelopment, epilepsy and mental health. The firm is investing in this area, with an additional focus on pregnancy, childbirth and women’s health.

The firm takes at minimum a board observer seat when investing, and look to help the company strategically with their expertise and network.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital/private equity firm based in the US invests in both digital health technologies and the life sciences. For their life sciences investments, most of them are in therapeutics, with about 5% of their investments going to life science tools and diagnostics. For therapeutics companies, the firm prefers to see efficacy and safety data before investing. For tools, diagnostics and digital health companies, the companies should be either revenue generating, or, at minimum, revenue in sight. The firm will consider global opportunities, but invests primarily in the US, and generally invests 5-15M in their early stage deals.

For therapeutics companies, the firm is modality and indication agnostic, although is less interested in microbiotic-related therapeutics. The firm prefers platform technologies, or an associative program; they do not invest in single assets. For digital health companies, the firm invests primarily in enterprise software, such as clinical data management, tools to enable better care and healthcare IT companies.

The firm generally leads or co-leads investments, and will take a board seat after investing. For therapeutics companies, the firm prefers the startups to have raised 1-5M in a previous round before investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.